Omeros clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 6 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 20 participants (planned). After: 3 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2026. After: 14 Apr 2026.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.. After: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels..

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 54 participants (planned). After: 31 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2020. After: 25 Aug 2020.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source